Marshall Fordyce, PRESIDENT AND CEO at Vera Therapeutics, Inc. (VERA), sold 35,075 shares at $45.43 ($1.6M) on 2024-09-25, disclosed to the SEC on 2024-09-27.
Scheduled sale ($1.6M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.43 | 8,643 | $393K | 24.3% |
| 2 | $45.43 | 975 | $44K | 2.7% |
| 3 | $45.43 | 8,643 | $393K | 24.3% |
| 4 | $45.44 | 975 | $44K | 2.7% |
| 5 | $45.48 | 975 | $44K | 2.7% |
| 6 | $46.62 | 4,817 |
| $225K |
| 13.9% |
| 7 | $46.62 | 4,817 | $225K | 13.9% |
| 8 | $46.79 | 900 | $42K | 2.6% |
| 9 | $47.06 | 2,165 | $102K | 6.3% |
| 10 | $47.06 | 2,165 | $102K | 6.3% |
| Total | $45.99 avg | 35,075 | $1.6M | 100% |
| Filing → |
| VERA | SELL | 2026-07-09 | $2.0M | — | Filing → |
| VERA | SELL | 2026-06-24 | $702K | — | Filing → |
| VERA | SELL | 2026-05-13 | $680K | — | Filing → |